127 related articles for article (PubMed ID: 30890414)
21. Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation.
Jones R; Prommer E; Backstedt D
Am J Hosp Palliat Care; 2016 Nov; 33(9):875-880. PubMed ID: 26150678
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients.
Al-Huniti N; Chapel S; Xu H; Bui KH; Sostek M
Br J Clin Pharmacol; 2016 Jan; 81(1):89-100. PubMed ID: 26317320
[TBL] [Abstract][Full Text] [Related]
23. Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain.
Leonard J; Baker DE
Ann Pharmacother; 2015 Mar; 49(3):360-5. PubMed ID: 25471070
[TBL] [Abstract][Full Text] [Related]
24. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
Holder RM; Rhee D
Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
[TBL] [Abstract][Full Text] [Related]
25. Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist.
Bui K; Zhou D; Xu H; Floettmann E; Al-Huniti N
Clin Pharmacokinet; 2017 Jun; 56(6):573-582. PubMed ID: 28035588
[TBL] [Abstract][Full Text] [Related]
26. A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation.
Webster L; Tummala R; Diva U; Lappalainen J
J Opioid Manag; 2016; 12(6):405-419. PubMed ID: 28059433
[TBL] [Abstract][Full Text] [Related]
27. Movantik™ and the Frequency of Positive Naloxone in Urine.
Wotring J; Countryman S; Wallace FN; Strickland EC; Cummings OT; McIntire GL
J Anal Toxicol; 2018 Apr; 42(3):e38-e40. PubMed ID: 29301016
[No Abstract] [Full Text] [Related]
28. Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced Constipation.
Al-Huniti N; Nielsen JC; Hutmacher MM; Lappalainen J; Cantagallo K; Sostek M
CPT Pharmacometrics Syst Pharmacol; 2016 Jul; 5(7):359-66. PubMed ID: 27435972
[TBL] [Abstract][Full Text] [Related]
29. Naloxegol for managing opioid-induced constipation.
Shelton KN; Clements JN
JAAPA; 2017 Sep; 30(9):51-53. PubMed ID: 28858018
[TBL] [Abstract][Full Text] [Related]
30. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
Corsetti M; Tack J
Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386
[TBL] [Abstract][Full Text] [Related]
31. The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol.
Bui K; She F; Sostek M
J Clin Pharmacol; 2014 Dec; 54(12):1368-74. PubMed ID: 24945932
[TBL] [Abstract][Full Text] [Related]
32. Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility.
Lawson R; King F; Marsh K; Altincatal A; Cimen A
Adv Ther; 2016 Aug; 33(8):1331-46. PubMed ID: 27342744
[TBL] [Abstract][Full Text] [Related]
33. Determination of naloxegol in human biological matrices.
Li Y; Hoffmann M; Severin P
Bioanalysis; 2017 Apr; 9(8):609-619. PubMed ID: 28504549
[TBL] [Abstract][Full Text] [Related]
34. Naloxegol , a new drug for the treatment of opioid-induced constipation.
Corsetti M; Tack J
Expert Opin Pharmacother; 2015 Feb; 16(3):399-406. PubMed ID: 25496063
[TBL] [Abstract][Full Text] [Related]
35. Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label.
Al-Huniti N; Zhou D; Xu H; Aksenov S; Bui KH; Fox R; Helmlinger G; Stanski D
Clin Pharmacol Ther; 2017 Nov; 102(5):741-744. PubMed ID: 28548207
[TBL] [Abstract][Full Text] [Related]
36. Naloxegol for the treatment of opioid-induced constipation.
Tack J; Corsetti M
Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):855-61. PubMed ID: 25220391
[TBL] [Abstract][Full Text] [Related]
37. Naloxegol to Treat Constipation in a Patient Taking Opioids for Cancer Pain: A Case Report.
Gálvez R; Maire C; Tovar I; Vargas P
A A Pract; 2018 Jul; 11(1):22-24. PubMed ID: 29634552
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use.
Nalamachu S; Gudin J; Datto C; Coyne K; Poon JL; Hu Y
J Opioid Manag; 2018; 14(3):211-221. PubMed ID: 30044486
[TBL] [Abstract][Full Text] [Related]
39. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol.
Bui K; She F; Sostek M
J Clin Pharmacol; 2014 Dec; 54(12):1375-82. PubMed ID: 24946021
[TBL] [Abstract][Full Text] [Related]
40. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
